{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T06:41:55Z","timestamp":1740120115168,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,4,30]],"date-time":"2018-04-30T00:00:00Z","timestamp":1525046400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s12185-018-2459-6","type":"journal-article","created":{"date-parts":[[2018,4,30]],"date-time":"2018-04-30T07:32:42Z","timestamp":1525073562000},"page":"176-183","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Switching to nilotinib is associated with deeper molecular responses in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan"],"prefix":"10.1007","volume":"108","author":[{"name":"the STAT study group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Noguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiaki","family":"Nakaseko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaichi","family":"Nishiwaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Ogasawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohshi","family":"Ohishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihide","family":"Tokuhira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Handa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinuko","family":"Mitani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatomo","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Wakita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6758-3787","authenticated-orcid":false,"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,30]]},"reference":[{"key":"2459_CR1","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","volume":"12","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12:841\u201351.","journal-title":"Lancet Oncol"},{"key":"2459_CR2","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/leu.2012.134","volume":"26","author":"RA Larson","year":"2012","unstructured":"Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012;26:2197\u2013203.","journal-title":"Leukemia"},{"key":"2459_CR3","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044\u201354.","journal-title":"Leukemia"},{"key":"2459_CR4","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1182\/blood-2013-12-544015","volume":"124","author":"TP Hughes","year":"2014","unstructured":"Hughes TP, Lipton JH, Spector N, Cervantes F, Pasquini R, Clementino NC, et al. Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. Blood. 2014;124:729\u201336.","journal-title":"Blood"},{"key":"2459_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","volume":"128","author":"TP Hughes","year":"2016","unstructured":"Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood. 2016;128:17\u201323.","journal-title":"Blood"},{"key":"2459_CR6","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1002\/cam4.801","volume":"5","author":"S Dulucq","year":"2016","unstructured":"Dulucq S, Mahon FX. Deep molecular responses for treatment-free remission in chronic myeloid leukemia. Cancer Med. 2016;5:2398\u2013411.","journal-title":"Cancer Med"},{"key":"2459_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2295-0","author":"D Rea","year":"2017","unstructured":"Rea D, Cayuela JM. Treatment-free remission in patients with chronic myeloid leukemia. Int J Hematol. 2017. \n                    https:\/\/doi.org\/10.1007\/s12185-017-2295-0\n                    \n                  . (epub ahead of print).","journal-title":"Int J Hematol"},{"key":"2459_CR8","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029\u201335.","journal-title":"Lancet Oncol"},{"key":"2459_CR9","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122:515\u201322.","journal-title":"Blood"},{"key":"2459_CR10","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","volume":"32","author":"P Rousselot","year":"2014","unstructured":"Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32:424\u201330.","journal-title":"J Clin Oncol"},{"key":"2459_CR11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s12185-017-2334-x","volume":"107","author":"N Takahashi","year":"2018","unstructured":"Takahashi N, Tauchi T, Kitamura K, Miyamura K, Saburi Y, Hatta Y, et al. Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study. Int J Hematol. 2018;107:185\u2013193.","journal-title":"Int J Hematol"},{"key":"2459_CR12","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/bmc.1364","volume":"24","author":"M Miura","year":"2010","unstructured":"Miura M, Takahashi N, Sawada K. High-performance liquid chromatography with solid-phase extraction for the quantitative determination of nilotinib in human plasma. Biomed Chromatogr. 2010;24:789\u201393.","journal-title":"Biomed Chromatogr"},{"key":"2459_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.dmpk.2015.09.002","volume":"31","author":"M Miura","year":"2016","unstructured":"Miura M, Takahashi N. Routine therapeutic drug monitoring of tyrosine kinase inhibitors by HPLC-UV or LC-MS\/MS methods. Drug Metab Pharmacokinet. 2016;31:12\u201320.","journal-title":"Drug Metab Pharmacokinet"},{"key":"2459_CR14","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/00008571-200206000-00009","volume":"12","author":"S Fukuen","year":"2002","unstructured":"Fukuen S, Fukuda T, Maune H, Ikenaga Y, Yamamoto I, Inaba T, et al. Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics. 2002;12:331\u20134.","journal-title":"Pharmacogenetics"},{"key":"2459_CR15","doi-asserted-by":"publisher","first-page":"308","DOI":"10.2133\/dmpk.19.308","volume":"19","author":"M Itoda","year":"2004","unstructured":"Itoda M, Saito Y, Maekawa K, Hichiya H, Komamura K, Kamakura S, et al. Seven novel single nucleotide polymorphisms in the human SLC22A1 gene encoding organic cation transporter 1 (OCT1). Drug Metab Pharmacokinet. 2004;19:308\u201312.","journal-title":"Drug Metab Pharmacokinet"},{"key":"2459_CR16","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1067\/mcp.2001.114164","volume":"69","author":"I Cascorbi","year":"2001","unstructured":"Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther. 2001;69:169\u201374.","journal-title":"Clin Pharmacol Ther"},{"key":"2459_CR17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1124\/dmd.104.001628","volume":"33","author":"D Kobayashi","year":"2005","unstructured":"Kobayashi D, Ieiri I, Hirota T, Takane H, Maegawa S, Kigawa J, et al. Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos. 2005;33:94\u2013101.","journal-title":"Drug Metab Dispos"},{"key":"2459_CR18","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/FTD.0b013e3181838063","volume":"30","author":"M Miura","year":"2008","unstructured":"Miura M, Kagaya H, Satoh S, Inoue K, Saito M, Habuchi T, et al. Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther Drug Monit. 2008;30:559\u201364.","journal-title":"Ther Drug Monit"},{"key":"2459_CR19","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1124\/dmd.106.009787","volume":"34","author":"H Girard","year":"2006","unstructured":"Girard H, Villeneuve L, Court MH, Fortier LC, Caron P, Hao Q, et al. The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver. Drug Metab Dispos. 2006;34:1220\u20138.","journal-title":"Drug Metab Dispos"},{"key":"2459_CR20","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.4049\/jimmunol.171.5.2366","volume":"171","author":"RB Mailliard","year":"2003","unstructured":"Mailliard RB, Son YI, Redlinger R, Coates PT, Giermasz A, Morel PA, et al. Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J Immunol. 2003;171:2366\u201373.","journal-title":"J Immunol"},{"key":"2459_CR21","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.3109\/10428194.2015.1091929","volume":"57","author":"C Chai-Adisaksopha","year":"2016","unstructured":"Chai-Adisaksopha C, Lam W, Hillis C. Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis. Leuk Lymphoma. 2016;57:1300\u201310.","journal-title":"Leuk Lymphoma"},{"key":"2459_CR22","doi-asserted-by":"publisher","first-page":"212","DOI":"10.2133\/dmpk.18.212","volume":"18","author":"M Itoda","year":"2003","unstructured":"Itoda M, Saito Y, Shirao K, Minami H, Ohtsu A, Yoshida T, et al. Eight novel single nucleotide polymorphisms in ABCG2\/BCRP in Japanese cancer patients administered irinotacan. Drug Metab Pharmacokinet. 2003;18:212\u2013217.","journal-title":"Drug Metab Pharmacokinet"},{"key":"2459_CR23","doi-asserted-by":"publisher","first-page":"5889","DOI":"10.1158\/1078-0432.CCR-04-0144","volume":"10","author":"FA Jong de","year":"2004","unstructured":"de Jong FA, Marsh S, Mathijssen RH, King C, Verweij J, Sparreboom A, et al. ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin Cancer Res. 2004;10:5889\u201394.","journal-title":"Clin Cancer Res"},{"key":"2459_CR24","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/jhg.2010.98","volume":"55","author":"N Takahashi","year":"2010","unstructured":"Takahashi N, Miura M, Scott SA, Kagaya H, Kameoka Y, Tagawa H, et al. Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. J Hum Genet. 2010;55:731\u20137.","journal-title":"J Hum Genet"},{"key":"2459_CR25","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.3324\/haematol.2013.085167","volume":"98","author":"Y Shinohara","year":"2013","unstructured":"Shinohara Y, Takahashi N, Nishiwaki K, Hino M, Kashimura M, Wakita H, et al. A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction. Haematologica. 2013;98:1407\u201313.","journal-title":"Haematologica"},{"key":"2459_CR26","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/j.1476-5381.2011.01618.x","volume":"165","author":"K Mandery","year":"2012","unstructured":"Mandery K, Glaeser H, Fromm MF. Interaction of innovative small molecule drugs used for cancer therapy with drug transporters. Br J Pharmacol. 2012;165:345\u201362.","journal-title":"Br J Pharmacol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-018-2459-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-018-2459-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-018-2459-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T08:57:19Z","timestamp":1556614639000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-018-2459-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,30]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["2459"],"URL":"https:\/\/doi.org\/10.1007\/s12185-018-2459-6","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2018,4,30]]},"assertion":[{"value":"14 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.T received grants from Novartis Pharmaceuticals, during the conduct of the study; grants and personal fees from Novartis Pharmaceuticals, grants and personal fees from Otsuka, grants and personal fees from Pfizer, personal fees from Bristol-Myers Squibb, outside the submitted work; C.N received personal fees from Novartis, grants and personal fees from Bristol-Myers Squibb, grants and personal fees from Pfizer, grants and personal fees from Takeda pharmaceuticals, grants and personal fees from Kyowa Hakko Kirin, grants and personal fees from Otsuka Pharmaceutical, grants and personal fees from Ono Pharmaceutical, grants and personal fees from Chugai Pharmaceutical, grants and personal fees from Asahi Kasei Pharma, grants and personal fees from Shionogi, personal fees from Shire, personal fees from Jannsen, personal fees from Celgene, outside the submitted work; K.N received grants from Zenyaku Kogyo Company, Limited, grants from Chugai Pharmaceutical, grants from Novartis Pharma K.K., grants from Kyowa Hakko Kirin Co, Ltd, grants from Nippon Shinyaku Co, Ltd, outside the submitted work; M.T. received personal fees from Bristol-Myers Squib, personal fees from Pfizer, outside the submitted work; K.M received grants from Kyowa Hakko Kirin Co. Ltd., grants from Chugai Pharmaceutical Co. Ltd., grants from Takeda Pharmaceutical Co. Ltd., grants from Novartis Pharma K. K., personal fees from Kyowa Hakko Kirin Co. Ltd., personal fees from Celgene Co., personal fees from Pfizer Inc., personal fees from Alexion Pharmaceuticals Inc., personal fees from BML Inc., personal fees from Shire Japan K.K., personal fees from Bristol-Myers Squibb K.K., personal fees from Abbvie Inc., personal fees from Mochida Pharmaceutical Co. Ltd., personal fees from Novartis Pharma K. K., personal fees from Takeda Pharmaceutical Co. Ltd., personal fees from Kyowa Hakko Kirin Co. Ltd., personal fees from Ono Pharmaceutical Co. Ltd., personal fees from Nippon Shinyaku Co. Ltd., outside the submitted work. The other authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}